CYTOMX THERAPEUTICS I

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

06 Nov 2024 13:45:07 By NetDania Notify

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

31 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

29 Oct 2024 14:57:21 By NetDania Notify

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

28 Oct 2024 10:30:57 By NetDania Notify

NetDania - New 12 months Low: CYTOMX THERAPEUTICS INC. - COMMON STOCK

25 Oct 2024 10:27:19 By NetDania Notify

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

09 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at Upcoming September Investor Conferences

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 15:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

01 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

17 Jun 2024 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

22 May 2024 15:05:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces New Employment Inducement Grants

16 May 2024 15:15:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

08 May 2024 15:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

08 May 2024 15:10:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

07 May 2024 15:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CYTOMX THERAPEUTICS INC. - COMMON STOCK

01 May 2024 08:45:03 By NetDania Notify

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

01 May 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

03 Apr 2024 07:00:01 By Nasdaq GlobeNewswire